Connect with us

Business

Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground

Published

on

Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground


Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medications: pills.

Both companies expect to launch oral obesity drugs in the U.S. next year, once regulators approve them. Daily pills could introduce more people to GLP-1s, the class of medicine that’s best known for weekly shots.

But after Lilly’s pill produced less weight loss than analysts had expected in a recent late-stage trial, it raised new questions about how widely the oral drugs will be adopted and which rival company will dominate the space.

Doctors will get a closer look at how Lilly and Novo’s pills compare in the coming months when Lilly releases the results of a head-to-head trial of the two, Lilly’s Chief Scientific Officer Dan Skovronsky said in an exclusive interview with CNBC. The study’s main objective is to measure how much the pills can reduce blood sugar levels in people with Type 2 diabetes, but it will also gauge weight loss.

“We wouldn’t have undertaken this head-to-head phase three randomized control trial unless we had a lot of confidence that orforglipron would fare well in comparison to oral semaglutide,” Skovronsky said.

Nikos Pekiaridis | Nurphoto | Getty Images

He cautioned against making comparisons across trials that didn’t directly compare the drugs, where Novo’s pill looks more effective and led to fewer discontinuations. Meanwhile, Novo’s Chief Scientific Officer Martin Holst Lange in a separate interview said the data speak for themselves.

Novo’s forthcoming obesity pill is an oral version of its weekly shot Wegovy; Lilly’s pill is a new drug called orforglipron that’s different from its shot Zepbound. Lilly’s shot is the gold standard in terms of efficacy, Skovronsky said. It can help people lose more than 20% of their body weight.

Neither Novo’s pill nor Lilly’s oral drug are as effective as Zepbound. At the highest dose, orforglipron has produced about 12% weight loss, while oral semaglutide has led to about 17%. That raises the question of how many people will opt for a pill if it means less weight loss.

Even so, Wall Street expects pills to make major inroads in the coming years. Analysts see oral drugs representing about 20% of the estimated $80 billion market for GLP-1 obesity drugs in 2030, according to data from Evaluate.

The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.

Mads Claus Rasmussen | Afp | Getty Images

Skovronsky thinks that pills could eventually become the primary way that obesity is treated around the world, and that oral drugs could have a larger market share than injectables. He said most patients are more concerned about other factors like supply and convenience than how much weight they can lose, and he thinks orforglipron has the edge.

The treatment is a small molecule drug like most pills people know. It can be manufactured more easily than peptides, like the shots and Novo’s pill. And it doesn’t come with the food and water restrictions that come with Novo’s oral option, which requires people wait 30 minutes after taking the drug to eat and drink.

“When I look at the pills, orforglipron has no food effect, it’s a small molecule, so the manufacturing should be easier,” said BMO Capital Markets analyst Evan Seigerman. “But with new management at Novo Nordisk, I think [new Chief Executive Officer] Mike Doustdar is not going to just take this and be complacent about it. He’s going to lean in and ensure that this launch is successful.”

After seeing the results from Lilly’s obesity pill trial, Seigerman moved some of his market share estimate from orforglipron to oral semaglutide. Analysts cut their 2032 estimates for orforglipron by an average of about $4.5 billion between May and September, according to Evaluate. They now see sales of $14.56 billion that year.

Skovronsky said it’s harder to predict the market dynamics than the science.

“We did a good job predicting the science,” he said. “We said we’d make an oral that had safety, tolerability and efficacy that was similar to injectable GLP-1s. We did that. The science parts played out. Let’s see how the market plays out.”



Source link

Business

South East Water faces £22m fine for supply failures

Published

on

South East Water faces £22m fine for supply failures



The firm was unable to cope during high demand, Ofwat says, leading to “immense stress” for customers.



Source link

Continue Reading

Business

Middle East heat may ripple across India’s energy supply chain, flags Goldman Sachs – The Times of India

Published

on

Middle East heat may ripple across India’s energy supply chain, flags Goldman Sachs – The Times of India


As tensions continue to heat up in the Middle East, concerns are raising about disruptions to one of the world’s most critical energy shipping routes, the Strait of Hormuz. Any disruption could significantly affect major oil-importing countries such as India, as the narrow Strait of Hormuz is central to global energy trade. The strait sees almost 20 million barrels of oil passing through each day, or about a fifth of the world’s consumption, pass through the route. The waterway also carries roughly 19% of global liquefied natural gas (LNG) shipments, making it a crucial corridor for energy-importing economies.A recent report by Goldman Sachs has flagged early signs of stress in the region. The report warned that tanker traffic through the Strait of Hormuz has already begun showing signs of disruption, with shipping firms, oil producers and insurers adopting a cautious approach following reports of damaged vessels in nearby waters.According to the firm, financial markets have already begun factoring in the geopolitical risk. Oil prices currently carry an estimated risk premium of $18-per-barrel, reflecting the potential market impact if energy flows through the Strait of Hormuz were disrupted for about a month.

The importance of Hormuz for global oil flows

Even is the oil facilities are not directly damaged, a shutdown of the shipping route could expose a significant portion of global supply. The report estimates that in an event of full closure, about 16 million barrels per day of oil flows could be affected, despite the availability of some pipeline routes designed to bypass the strait.And the risks are not limited to crude oil shipments with almost 80 million tonnes of LNG exports annually, much of it from Qatar, moving through the passage. Any prolonged disruption could tighten gas supply globally and potentially drive European benchmark gas prices back to levels seen during the 2022 energy crisis.

The Strait of Hormuz

Asian economies stand among the most exposed to such disruptions. Major importers such as China, India, Japan and South Korea depend heavily on oil and LNG shipments that transit through the strategic corridor.While global oil inventories and spare production capacity could help cushion short-term shocks, the report warned that sustained disruption to Gulf shipping routes could trigger sharp volatility in global energy markets and push prices higher across oil, gas and refined fuel products.Market participants and governments are closely watching tanker traffic in the Strait of Hormuz, along with diplomatic and military developments involving the United States, Iran and Gulf nations, to assess whether the current disruptions remain temporary or escalate into a broader energy supply shock.



Source link

Continue Reading

Business

Saudi Oil Supply Assurance Lifts Pakistan Stock Market – SUCH TV

Published

on

Saudi Oil Supply Assurance Lifts Pakistan Stock Market – SUCH TV



KARACHI: The Pakistan Stock Exchange rallied on Thursday after Saudi Arabia assured Pakistan of facilitating crude oil shipments through the Red Sea port of Yanbu Port, easing concerns over potential fuel supply disruptions.

The benchmark KSE-100 Index climbed sharply during the trading session, rising 4,439.93 points (2.85%) to reach an intraday high of 160,217.14 points.

Market Recovery

Analysts attributed the market rebound to renewed institutional buying and improving investor sentiment after Saudi assurances on oil supplies.

Market expert Ahsan Mehanti, CEO of Arif Habib Commodities, said easing fuel supply concerns played a key role in the recovery.

He added that rising global crude prices, expectations of a new International Monetary Fund loan tranche for Pakistan, and positive economic indicators also boosted investor confidence.

Alternative Oil Route

Pakistan sought an alternative supply route after Iran announced the closure of the Strait of Hormuz, a crucial global oil transit corridor.

Federal Petroleum Minister Ali Pervaiz Malik held talks with Nawaf bin Said Al-Malki, requesting Saudi support for uninterrupted energy supplies.

Saudi authorities reportedly assured Pakistan that oil shipments could be routed through Yanbu, and one crude vessel has already been prepared for dispatch.

Global Oil Market Impact

Oil prices continued to rise amid tensions in the Middle East conflict involving Iran, Israel and the United States.

Brent crude: up 3.26% to $83.99 per barrel

West Texas Intermediate (WTI): up 3.70% to $77.42 per barrel

Energy markets remain volatile as shipping disruptions threaten supply through the Strait of Hormuz, a route that handles nearly 20% of global oil trade.

Analysts say the Saudi assurance helped calm fears about Pakistan’s energy supply chain, contributing to the strong recovery at the PSX.

 




Source link

Continue Reading

Trending